1-异丙基肼 | 6629-61-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-异丙基肼
• 中文别名: 异丙基肼草酸盐
• 英文名称: isopropylhydrazine oxalate
• 英文别名: Isopropyl-hydrazin; Oxalat；oxalic acid;propan-2-ylhydrazine
• CAS: 6629-61-4
• 化学式: C₂H₂O₄*C₃H₁₀N₂
• 分子量: 164.161
• InChiKey: IAQPDIVFEYAFMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.99
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-异丙基肼 、 丙酮醛 在 碳酸氢钠 作用下， 以 水 为溶剂， 反应 48.0h， 以30%的产率得到1-[4-hydroxy-5-methyl-1-(propan-2-yl)-1H-pyrazol-3-yl]ethanone
  参考文献：
  名称：

  [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS
  [FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE

  摘要：

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。

  公开号：

  WO2009144554A1

文献信息

• [EN] AMINO-INDOLYL-SUBSTITUTED IMIDAZOLYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS<br/>[FR] IMIDAZOLYL-PYRIMIDINES SUBSTITUÉES AVEC UN GROUPE AMINO-INDOLYLE ET LEUR UTILISATION COMME MÉDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013156608A1

  公开（公告）日：2013-10-24

  The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula (1), wherein R1, R2, R3, R4 and R5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

  该发明涉及公式（1）中的新氨基吲哚取代的咪唑基嘧啶化合物，其中R1、R2、R3、R4和R5如权利要求书中所定义，并且其药学上可接受的盐以及这些化合物用于制备用于治疗包括哮喘、慢性阻塞性肺病（COPD）、类风湿性关节炎、特定淋巴瘤和特定神经系统疾病在内的疾病的药物。
• Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：US20130281430A1

  公开（公告）日：2013-10-24

  The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined as in claim 1 and pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

  该发明涉及新的氨基吲哚取代的咪唑基嘧啶化合物，化学式为1，其中R1、R2、R3、R4和R5如权利要求1所定义，以及其药学上可接受的盐，以及利用这些化合物制备用于治疗哮喘、慢性阻塞性肺疾病、类风湿性关节炎、特定淋巴瘤和特定神经系统疾病的药物。
• Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme
  作者：Kevin D. Rynearson、Ronald N. Buckle、Keith D. Barnes、R. Jason Herr、Nicholas J. Mayhew、William D. Paquette、Samuel A. Sakwa、Phuong D. Nguyen、Graham Johnson、Rudolph E. Tanzi、Steven L. Wagner

  DOI：10.1016/j.bmcl.2016.07.011

  日期：2016.8

  The design and construction of a series of novel aminothiazole-derived gamma-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. gamma-Secretase modulator 28 displayed good activity for in vitro inhibition of Abeta42, as well as substantial improvement

  描述了一系列新颖的氨基噻唑衍生的γ-分泌酶调节剂的设计和构建。进行铅化合物1的末端苯基D-环的杂环取代基的掺入，以使效力与有利的类药物性质对准。γ-分泌酶调节剂28表现出良好的体外抑制Abeta42活性，以及​​ADME和理化特性（包括水溶性）的显着改善。化合物28在小鼠中的药代动力学评估显示，其良好的大脑渗透能力以及良好的清除率，半衰期和分布体积共同支持了这类化合物的持续开发。
• Cyclocondensation of alkylhydrazines and .beta.-substituted acetylenic esters: synthesis of 3-hydroxypyrazoles
  作者：Bruce C. Hamper、Mitchell L. Kurtzweil、James P. Beck

  DOI：10.1021/jo00047a021

  日期：1992.10

  Addition of monosubstituted alkylhydrazines to acetylenic esters with either electron-withdrawing or sterically bulky beta-substituents afforded 1-alkyl-3-hydroxy-5-substituted-pyrazoles 1 as the major regioisomeric product. By comparison, the classical cyclocondensation of alkylhydrazines with beta-keto esters gives the regioisomeric pyrazol-5-ones 2. The reaction solvent employed in these cyclocondensations can have a profound effect on regioisomeric product ratios. Addition of methylhydrazine to 5g in methylene chloride gave regiospecific formation of pyrazolinone 2o, whereas addition in water-methanol mixtures afforded hydroxypyrazole 1o as the major product. Structural assignment of regioisomers 1 and 2 are based on C-13 NMR chemical shifts, long-range heteronuclear coupling constants, and comparisons with regiochemically known hydroxypyrazoles and/or pyrazolinones. Additions of acetylene 5b to 1,1-dimethylhydrazine afforded either acyclic enehydrazone 12 or pyrazolium betaine 13 depending on the reaction conditions.
• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。